Abstract:Bong-Jo Kim, 1 Seon-Been Bak, 1 Su-Jin Bae, 1, 2 Hyo-Jung Jin, 3 Sang Mi Park, 3 Ye-Rim Kim, 3 Dae-Hwa Jung, 3 Chang-Hyun Song, 3 Young-Woo Kim, 1 Sang-Chan Kim, 3 Won-Yung Lee, 2, 4 Sun-Dong Park 1 1 Department of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea; 2 Department of Korean Medicine, Wonkwang University, Iksan, 54538, Korea; 3 Medical Research Center, College of Korean Medicine, Daegu Haany University, Gyeongsan, 38610, Korea; 4 Research Center of Traditional Korean Medicine, Wonkwang University, Iksan, 54538, Korea Correspondence: Won-Yung Lee, Department of Korean Medicine, Wonkwang University, Iksan, 54538, Korea, Email Sun-Dong Park, Department of Korean Medicine, Dongguk University, Gyeongju, 38066, Korea, Email Introduction: Tacrine, an FDA-approved acetylcholinesterase inhibitor, has shown efficacy in treating Alzheimer's disease, but its clinical use is limited by hepatotoxicity. This study investigates the protective effects of red ginseng against tacrine-induced hepatotoxicity, focusing on oxidative stress. Methods: A network depicting the interaction between compounds and targets was constructed for RG. Effect of RG was determined by MTT and FACS analysis with cells stained by rhodamine 123. Proteins were extracted and subjected to immunoblotting for apoptosis-related proteins. Results: The outcomes of the network analysis revealed a significant association, with 20 out of 82 identified primary RG targets aligning with those involved in oxidative liver damage including notable interactions within the AMPK pathway. in vitro experiments showed that RG, particularly at 1000μg/mL, mitigated tacrine-induced apoptosis and mitochondrial damage, while activating the LKB1-mediated AMPK pathway and Hippo-Yap signaling. In mice, RG also protected the liver injury induced by tacrine, as similar protective effects to silymarin, a well-known drug for liver toxicity protection. Discussion: Our study reveals the potential of RG in mitigating tacrine-induced hepatotoxicity, suggesting the administration of natural products like RG to reduce toxicity in Alzheimer's disease treatment. Keywords: AMPK, liver toxicity, oxidative stress, red ginseng, tacrine Alzheimer's disease, a prevalent and debilitating neurodegenerative disorder, affects approximately 50 million people worldwide, with the number projected to increase to nearly 152 million by 2050. 1 This global health challenge profoundly impacts cognitive function, daily living, and quality of life for affected individuals and their caregivers. 2 Tacrine, an oral acetylcholinesterase inhibitor, has garnered significant attention for its role in the treatment of Alzheimer's disease. 3 By inhibiting the enzyme acetylcholinesterase, tacrine increases the levels of acetylcholine in the brain, thereby ameliorating the cholinergic deficits associated with the disease. 4 However, despite its demonstrated efficacy in alleviating Alzheimer's symptoms, the clinical use of tacrine has been hindered by its toxicity, particularly hepatotoxicity, which affects 30–50% of patients receiving treatment. 5 The hepatotoxicity of tacrine is believed to be associated with the formation of reactive metabolites, leading to oxidative stress and mitochondrial dysfunction in hepatic cells. 6 Consequently, there is a pressing need to identify therapeutic agents that can effectively mitigate the hepatotoxic effects of tacrine, thereby expanding its potential application in the management of Alzheimer's disease and improving patient outcomes. Red ginseng (RG), a dried and steamed form of Panax ginseng , belonging to the family Araliaceae, is renowned for its health-promoting properties and extensive pharmacological potential. 7 Known for its improved digestibility and storage properties compared to raw ginseng, RG has been the focus of various studies investigating its protective effects against oxidative liver injury. 8 Research has shown that RG and its components, such as fermented RG and 20(S)-protopanaxadiol, can exert antioxidative and anti-inflammatory effects on liver tissue, contributing to the overall protection of liver function. 9–11 The unique phytochemical profile of RG, comprising saponins (notably ginsenosides), flavonoids, polyacetylenes, and polysaccharides, underpins its therapeutic potential. 12 Another study suggested that the hepatoprotective properties of RG are exerted through the activation of the AMPK pathway, which defends against oxidative damage and supports liver health -Abstract Truncated-

Fermented Korean Red Ginseng Extract Enriched in Rd and Rg3 Protects against Non-Alcoholic Fatty Liver Disease through Regulation of mTORC1

Beneficial Effects of Korean Red Ginseng in the Progression of Non-Alcoholic Steatohepatitis via FABP4 Modulation.

Korean red ginseng formula attenuates non-alcoholic fatty liver disease in oleic acid-induced HepG2 cells and high-fat diet-induced rats

Ginsenoside Rg3 Attenuates Early Hepatic Injury Via Inhibiting PPARγ- and Ang II-Related Inflammation and Fibrosis in Type II Diabetic Mice

Ginsenoside Rg5 Activates the LKB1/AMPK/mTOR Signaling Pathway and Modifies the Gut Microbiota to Alleviate Nonalcoholic Fatty Liver Disease Induced by a High-Fat Diet

Ginsenoside R3 alleviates non-alcoholic fatty liver disease by regulating the PPARγ/miR-103-3p pathway

Fermented Red Ginseng Alleviates Cyclophosphamide-Induced Immunosuppression and 2,4,6-Trinitrobenzenesulfonic Acid-Induced Colitis in Mice by Regulating Macrophage Activation and T Cell Differentiation

Fermented Ginsenosides Alleviate Acute Liver Injury Induced by CCl4 in Mice by Regulating the AKT/mTOR Signaling Pathway

Ginsenoside Rg1 protects against d-galactose induced fatty liver disease in a mouse model via FOXO1 transcriptional factor

Ginseng Saponin Enriched in Rh1 and Rg2 Ameliorates Nonalcoholic Fatty Liver Disease by Inhibiting Inflammasome Activation

Protective Effects of Red Ginseng Against Tacrine-Induced Hepatotoxicity: An Integrated Approach with Network Pharmacology and Experimental Validation

6,7-Dimethoxycoumarin, Gardenoside and Rhein combination improves non-alcoholic fatty liver disease in rats

<i>Lactobacillus fermentum</i> KP-3-fermented ginseng ameliorates alcohol-induced liver disease in C57BL/6N mice through the AMPK and MAPK pathways

Ginsenoside Rg3 promotes hepatic stellate cell ferroptosis by epigenetically regulating ACSL4 to suppress liver fibrosis progression

Long-term and Liver-Selected Ginsenoside C-K Nanoparticles Retard NAFLD Progression by Restoring Lipid Homeostasis.

Enhancing Immunomodulatory Function of Red Ginseng Through Fermentation Using Bifidobacterium animalis Subsp. lactis LT 19-2

Ameliorative effects of Compound K and ginsenoside Rh1 on non-alcoholic fatty liver disease in rats

Ginsenoside Rg1 attenuates lipopolysaccharide-induced chronic liver damage by activating Nrf2 signaling and inhibiting inflammasomes in hepatic cells

Effects of red ginseng ethanol extract on lipid metabolism in C57BL/6J mice fed high‐fat diets

Korean Red Ginseng Attenuates Hepatic Lipid Accumulation Via AMPK Activation in Human Hepatoma Cells

Ginsenoside Rk3 Regulates Nonalcoholic Steatohepatitis by Modulation of Intestinal Flora and the PI3K/AKT Signaling Pathway in C57BL/6 Mice.